AstraZeneca-Amgen asthma drug gets US approval
The AstraZeneca-Amgen asthma drug Tezspire has been approved by the US Food and Drug Administration to treat of adult and paediatric patients aged 12 years and older, the two companies said on Monday.
AMGEN Inc.
n/a
17:30 14/11/24
0.00%
€0.00
AstraZeneca
10,292.00p
16:49 14/11/24
1.46%
148.00p
FTSE 100
8,071.19
16:49 14/11/24
n/a
n/a
FTSE 350
4,459.02
16:38 14/11/24
n/a
n/a
FTSE All-Share
4,417.25
16:54 14/11/24
n/a
n/a
Pharmaceuticals & Biotechnology
19,794.96
16:38 14/11/24
0.96%
187.95
Approval was based on late-stage trial data that showed the drug cut the rate of asthma attacks by 56% among patients when compared with placebo.
Tezspire works by targeting thymic stromal lymphopoietin (TSLP) in the lining of the lungs.
Amgen will record sales for the drug in the United States, while AstraZeneca will record sales outside the country. Both the companies will also receive collaboration revenue from the profits.